Drugs / HMPL-760
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07643272 | Jun → Oct 2026 expected | — | Hutchmed | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05176691 | Feb → Nov 2022 | Richter transformation, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +2 | Hutchmed | Withdrawn | No outcome recorded |
| Phase 1 | NCT05190068 | Jan 2022 → Jan 2025 | B-cell non-Hodgkin lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06601504 | Nov 2024 → May 2026 overdue | diffuse large B-cell lymphoma | Hutchmed | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07409428 | Mar 2026 → Apr 2028 expected | diffuse large B-cell lymphoma | Hutchmed | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-760 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05190068 ↗ |
| Action | Inhibit | “highly potent, selective, and reversible inhibitor against BTK” NCT05176691 ↗ |
| Route | Oral | “Administered orally QD for 28-day cycles” NCT05176691 ↗ |
| Target | BTK | “inhibitor against BTK” NCT05176691 ↗ |